Bristol Myers Squibb raised its full-year 2026 revenue guidance to $49-$50 billion, up from $46-$47.5 billion, after Eliquis sales grew 19% to $8.6 billion in the first half. The company now expects Eliquis revenue growth of 20-25% for the year, versus a prior 10-15% forecast, and legacy portfolio revenues to decline 4-6% instead of 12-16%. Eliquis, co-commercialized with Pfizer, posted 22% growth in the second quarter, helping offset generic erosion for Revlimid, Pomalyst, Sprycel and Abraxane. Management still expects Eliquis sales to decline by $1.5-$2 billion in 2027.
Bristol-Myers Squibb CompanyRaises 2026 revenue guidance and Eliquis growth forecast, boosting earnings outlook.
Pfizer IncEliquis, co-commercialized with Pfizer, shows strong sales growth, benefiting Pfizer.
Merck & Company Inc